NeoGenomics, Inc. (NEO)
| Market Cap | 1.05B |
| Revenue (ttm) | 672.36M |
| Net Income (ttm) | -77.59M |
| Shares Out | 128.69M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | 43.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,088,880 |
| Open | 8.15 |
| Previous Close | 8.00 |
| Day's Range | 8.02 - 8.30 |
| 52-Week Range | 6.08 - 19.11 |
| Beta | 1.60 |
| Analysts | Buy |
| Price Target | 13.31 (+63.72%) |
| Earnings Date | Apr 29, 2025 |
About NEO
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through two segments: Clinical Services and Advanced Diagnostics. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on d... [Read more]
Financial Performance
In 2024, NeoGenomics's revenue was $660.57 million, an increase of 11.65% compared to the previous year's $591.64 million. Losses were -$78.73 million, -10.51% less than in 2023.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NEO stock is "Buy." The 12-month stock price forecast is $13.31, which is an increase of 63.72% from the latest price.
News
NeoGenomics Pays Off 1.25% Convertible Senior Notes
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)
NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's lo...
NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript
NeoGenomics, Inc (NASDAQ:NEO) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive O...
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
FORT MYERS, Fla. and FREMONT, Calif.
NeoGenomics Reports First Quarter 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025.
NeoGenomics Completes Acquisition of Pathline
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Tony Zook has officially assumed the role of Chief Executive Officer.
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
NeoGenomics: Decent Fundamentals, But Still Overvalued
NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGeno...
NeoGenomics to Participate in Upcoming Investor Conferences
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in several upcoming investor conferences.
NeoGenomics, Inc (NEO) Q4 2024 Earnings Call Transcript
NeoGenomics, Inc (NASDAQ:NEO) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Execut...
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full year results for the period ended December 31, 2024.
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Feb. 18, 2025.
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.
NeoGenomics Announces Chief Executive Officer Succession
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' Chris Smith will retire as CEO and board member, effective April 1, 2025. Tony Zook will assume the role of CEO at that time.
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
NeoGenomics' Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for high-risk melanoma patients.
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary CNS lymphoma at ASH.
ConcertAI and NeoGenomics Announce New AI Software-as-a-Service Solution for Hematology Clinical Research
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ConcertAI and NeoGenomics (NASDAQ: NEO) announce a joint software-as-a-service solution in hematological malignancies for research analytics, clinical trial design, ...
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present four abstracts at the Association for Molecular Pathology 2024 Annual Meeting & Expo, November 19-23 (booth #830).
Felicia Williams Joins NeoGenomics Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Felicia Williams to its Board of Directors.
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference in New York City.
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO) Q3 2024 Earnings Conference Call November 5, 2024 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Execut...